Protein produced by immune cells during malaria infection triggers severe anemia

Scientists have found that a protein produced by immune cells during malaria infection triggers severe anemia, a lethal complication of the disease.

Richard Bucala and colleagues at Yale University show that immune cells in mice with malaria secrete a protein called MIF, which decreases the production of red blood cells (RBCs) from the bone marrow. The study appears in The Journal of Experimental Medicine.

According to the World Health Organization, there are approximately 300 million to 500 million cases of malaria each year, with pregnant women and young children at highest risk. Severe anemia--a common complication of malaria--is one of the major causes of death among children.

Malaria parasites use RBCs as multiplication factories, rupturing the cells as progeny parasites exit. Infection also hampers the production of new RBCs from the bone marrow, an effect this group recently attributed to MIF, which is produced by immune cells that gobble up infected RBCs. Bucala's new study shows that mice genetically engineered to lack MIF were less anemic and survived longer than normal mice when infected with malaria-causing parasites.

The Yale team is now trying to determine whether MIF levels influence susceptibility to or severity of malarial anemia in humans. If so, synthetic inhibitors of MIF--currently in clinical development--might provide an effective alternative to the costly (and risky) blood transfusions currently used to treat malarial anemia.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough in protein engineering may lead to more effective cancer therapies